J&J Sjogren’s Drug Succeeds in Phase 2 (JNJ)
Snack-Sized Version:
J&J Sjogren’s drug, nipocalimab, succeeds in a Phase 2 trial. Johnson & Johnson announced the positive results for the DAHLIAS study. The trial met its primary endpoint. It significantly reduced disease activity in patients with Sjogren’s disease. Patients also reported relief from dryness, fatigue, and pain. These findings were published in The Lancet. J&J detailed the full results in a press release. This drug targets a chronic autoimmune disorder.
| Nipocalimab: At a Glance | |
|---|---|
| Platform | Investigational FcRn antagonist. |
| Features | Targets IgG autoantibodies in Sjogren’s disease. |
| Governance | Granted FDA Breakthrough Therapy Designation. |
| Release | Phase 2 (DAHLIAS) results published Oct 24, 2025. |
| Earnings timing | Next investor event is Nov 11, 2025. |
Source: Company press release; The Lancet.
Related Company News
Read the Full Meal:
Johnson & Johnson announced strong Phase 2 results for nipocalimab. The data, published in The Lancet, shows the drug met its goals. It reduced disease activity for Sjogren’s patients. This is a significant milestone for J&J’s immunology pipeline. The drug is a potential first-in-class treatment. Sjogren’s disease currently lacks effective targeted therapies. Therefore, these results may accelerate plans for Phase 3 trials.
The DAHLIAS Study Breakdown
- Primary Endpoint: The trial met its ClinESSDAI score target at 24 weeks.
- Key Symptoms: Patients reported notable relief from dryness, fatigue, and joint pain.
- Objective Measures: The high-dose group showed a 33% improvement in salivary flow.
- Biomarkers: Researchers also observed lower levels of inflammatory markers.
Quick links
- Official source: DAHLIAS Phase 2 press release
- IR hub: investor overview · filings
- Our coverage: Johnson & Johnson Previous News · Johnson & Johnson News Hub · Latest: Johnson & Johnson Analyst Ratings, Dividend (JNJ)
Why this can matter for JNJ holders
- Pipeline Value: Positive data confirms the strength of J&J’s immunology research.
- Market Expansion: Nipocalimab could become a first-in-class therapy for Sjogren’s.
- Defensive Growth: Clinical wins support JNJ’s long-term growth and defensive appeal.
What to watch next
- The Lancet Publication: Watch for the full study publication. [TODO: Add direct Lancet URL when available].
- Next Event: J&J will participate in the Guggenheim Healthcare Conference on Nov 11, 2025.
- Phase 3 Trials: Monitor updates on the start of the Phase 3 DAFFODIL study.
Mini FAQ
What is nipocalimab?
It is an investigational drug that blocks the FcRn receptor to lower autoantibodies.
What is Sjogren’s disease?
It is a chronic autoimmune disorder causing dryness, fatigue, and joint pain.
Industry News
-
Eli Lilly (LLY) Beats Q3 Expectations & Partners with NVIDIA November 19, 2025 -
Pfizer (PFE) Pivots: Metsera Deal & BioNTech Exit Signal New Era November 18, 2025 -
Merck (MRK) Stock Gains on Q3 Beat, Oral Drug Trial November 13, 2025 -
Johnson & Johnson Analyst Ratings, Dividend (JNJ) November 10, 2025 -
Acadian Boosts Stake in Bristol Myers Squibb (BMY) November 10, 2025 -
Cantor Fitzgerald Holds $925 Target on Eli Lilly (LLY) November 3, 2025
Sector News
-
UHS Declares $0.20 Cash Dividend for Q4 2025 December 1, 2025 -
Insulet Q3 2025: Strong Omnipod 5 Demand Drives Revenue Beat December 1, 2025 -
Tenet Healthcare Completes $2.25 Billion Refinancing November 29, 2025 -
Medpace Holdings Insider Sales Top $18 Million November 27, 2025 -
Biogen Expands Pipeline with Dayra Therapeutics Deal November 27, 2025 -
iRhythm Zio Data Validates Performance in Asian Populations November 26, 2025
Author
